Cancer Monoclonal Antibodies Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Cancer Monoclonal Antibodies Market is segmented By Types of Monoclonal Antibody, By Monoclonal Antibody Therapies, By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, and Other Applications), and Geography.

Market Snapshot

cancer monoclonal antibodies market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The cancer monoclonal antibodies market is expected to witness a CAGR of 9.2% during the forecast period. Certain factors that are driving the market growth include the growing prevalence of cancer, increasing investment in R&D of genomic studies, and rising advancements in and preference toward the specificity of monoclonal antibodies to target cancer.

According to the World Health Organization, cancer is the second leading cause of death worldwide, accounting for an estimated 9.6 million deaths, or one in six deaths, in the year 2018. Lung cancer, prostate cancer, colorectal cancer, and liver cancer are the most common types of cancer in men, while breast cancer, colorectal cancer, lung cancer, cervical cancer and thyroid cancer are the most common among women. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.

However, following the regulatory guidelines for monoclonal antibodies related to cancer is a highly rigorous process in most of the regions, globally. The guidelines provide a comprehensive description of the manufacturing processes including quality, good manufacturing practices, process validation, potential for degradation, and the need for stability studies. A stringent regulatory scenario exists globally, such as the US FDA, the European Medicines Agency (EMA), and the Korean FDA. Similar to biologics, biosimilar also faces similar restrictions for getting the approval of monoclonal antibodies in the market. Since it is a time-consuming process, it is considered as one of the major hindering factors for this market. Other factors that restrains the growth of the cancer monoclonal antibodies market are long duration of research and development before clinical trials and the rise in the failures of mAbs in clinical trials.

Scope of the Report

As per the scope of the report, monoclonal antibodies are highly specific to cancer cells, as they bind to the proteins on their surface and stimulate an immune response. This market consists of several types of monoclonal antibodies and much more in the pipeline. The cancer monoclonal antibodies market is segmented by types of a monoclonal antibody, monoclonal antibody therapies, application and geography.

By Types of Monoclonal Antibody
Murine Antibodies
Chimeric Antibodies
Humanized Antibodies
By Monoclonal Antibody Therapies
Bevacizumab (Avastin)
Rituximab (Rituxan)
Trastuzumab (Herceptin)
Cetuximab (Erbitux)
Panitumumab (Vectibix)
Other Monoclonal Antibody Therapies
By Application
Breast Cancer
Blood Cancer
Liver Cancer
Brain Cancer
Colorectal Cancer
Other Applications
North America
United States
United Kingdom
Rest of Europe
South korea
Rest of Asia-Pacific
Middle-East & Africa
South Africa
Rest of Middle-East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Trastuzumab (Herceptin) is Expected to Hold Significant Market Share in Monoclonal Antibody Therapies

Trastuzumab (Herceptin) is a monoclonal antibody used to treat breast cancer. It is also an approved first-line treatment for HER2+ metastatic cancer of the stomach or gastro-oesophagal junction. According to Roche’s (manufacturer of the drug) annual report 2019, the annual sales revenue generated from the drug Herceptin (oncology) was 69,82 (in million Swiss francs) in 2018 and 60,39 (in million Swiss francs). The country witnessed continued growth, mainly, due to the longer duration of treatment in combination with Perjeta.

However, the common side effects (fever, infection, cough, and rash, among others) and severe side effects (heart failure, allergic reaction, and lung disorders) are associated with the drug. The drug may also result in unnecessary issues for the baby if taken during pregnancy. These side effects may affect the adoption rate and, hence, may act as an inhibiting factor.

Cancer key trend 1.png

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The market is growing at a strong pace in North America. The pharmaceutical and biotechnology firms have gained abundant knowledge and expertise in cancer monoclonal antibodies. 

According to the Breast Cancer Organization in 2018, it was estimated that over 2,66,120 cases of invasive breast cancer were diagnosed in women in the United States, along with 63,960 new cases of non-invasive (in situ) breast cancer. With the approval of murine cancer monoclonal antibodies, followed by chimeric and fully human cancer monoclonal antibodies, the sales and the rate of product approvals have increased over the past few years. 

Moreover, depending on the high percentage of molecules that are in the pipeline, this scenario may change. Human monoclonal antibody (mAb) is the fastest-growing category in the market. Additionally, with the trend toward developing targeted therapeutics, the focus on fully-humanized cancer monoclonal antibodies is expected to increase, owing to perceived low-level of immunogenicity of these agents. The first human mAb was approved by the United States FDA, in 2002. Since then, many human mAbs have received the FDA approval and few are in the phase-3 studies. Sales of Rituxan (rituximab) grew by 5% in 2015, propelled by the strong demand in the country.

Cancer Monoclonal Antibodies Market2

Competitive Landscape

The cancer monoclonal antibodies market is highly consolidated. Some of the companies which are currently dominating the market are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab AS, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Seattle Genetics Inc., and Spectrum Pharmaceuticals Inc., among others, hold the substantial market share in the market studied.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Prevalence of Cancer

      2. 4.2.2 Increasing Investment in Research and Development of Genomic Studies

      3. 4.2.3 Rising Advancements and Preference toward Specificity of Monoclonal Antibodies to Target Cancer

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Guidelines

      2. 4.3.2 Long Duration of Research and Development with Rising Failures in Clinical Trials

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Types of Monoclonal Antibody

      1. 5.1.1 Murine Antibodies

      2. 5.1.2 Chimeric Antibodies

      3. 5.1.3 Humanized Antibodies

    2. 5.2 By Monoclonal Antibody Therapies

      1. 5.2.1 Bevacizumab (Avastin)

      2. 5.2.2 Rituximab (Rituxan)

      3. 5.2.3 Trastuzumab (Herceptin)

      4. 5.2.4 Cetuximab (Erbitux)

      5. 5.2.5 Panitumumab (Vectibix)

      6. 5.2.6 Other Monoclonal Antibody Therapies

    3. 5.3 By Application

      1. 5.3.1 Breast Cancer

      2. 5.3.2 Blood Cancer

      3. 5.3.3 Liver Cancer

      4. 5.3.4 Brain Cancer

      5. 5.3.5 Colorectal Cancer

      6. 5.3.6 Other Applications

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East & Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 Bristol Myers Squibb Company

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Genmab AS

      6. 6.1.6 GlaxoSmithKline PLC

      7. 6.1.7 Johnson & Johnson

      8. 6.1.8 Novartis AG

      9. 6.1.9 Merck & Co., Inc

      10. 6.1.10 Spectrum Pharmaceuticals Inc.

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Cancer Monoclonal Antibodies Market market is studied from 2018 - 2026.

The Cancer Monoclonal Antibodies Market is growing at a CAGR of 9.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Amgen Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd (Genentech Inc), Merck & Co., Inc, Novartis AG are the major companies operating in Cancer Monoclonal Antibodies Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!